Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02989194 · ClinicalTrials.gov registry record · Phase 2
Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A
A Phase 2 study of Influenza, sponsored by Visterra.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT02989194: Completed Phase 2 study of Influenza, sponsored by Visterra.
NCT02989194 is a Phase 2 study of Influenza that has completed, run by Visterra. The registered enrollment target is 150 participants, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02989194, a Phase 2 study of Influenza, has completed, sponsored by Visterra.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2a randomized, double-blind, placebo-controlled study designed to assess the safety and tolerability of an investigational monoclonal antibody, VIS410, in subjects with uncomplicated influenza.
Primary Outcome
The percentage of participants with adverse events (AEs) and serious adverse events (SAEs) following administration of a single dose of IV VIS410.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VIS410 low dose
- DRUG VIS410 high dose
Study Locations (20)
Other
- - Asenovgrad
- - Lom
- - Rousse
- - Sofia
- - Sofia
- - Velingrad
- - Paide
- - Tallinn
- - Tallinn
Florida
- - Coral Gables
- - Homestead
- - Miami
- - Miami
- - Orlando
Louisiana
- - Eunice
- - New Orleans
Texas
- - Houston
- - McAllen
Alabama
- - Huntsville
North Carolina
- - Shelby
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-01-06 |
| Est. Completion | 2017-10-27 |
| Phase | Phase 2 |
What the finished NCT02989194 record still lists
NCT02989194 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02989194 names 20 study sites across 6 states, led by Other, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT02989194 about?
NCT02989194 is a clinical study titled "Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A". This is a Phase 2a randomized, double-blind, placebo-controlled study designed to assess the safety and tolerability of an investigational monoclonal antibody, VIS410, in subjects with uncomplicated influenza.
What is the current status of trial NCT02989194?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2017-01-06. Estimated completion is 2017-10-27.
What conditions does trial NCT02989194 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT02989194?
The interventions under investigation include: Placebo (DRUG), VIS410 low dose (DRUG), VIS410 high dose (DRUG).
Who is sponsoring clinical trial NCT02989194?
This trial is sponsored by Visterra, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02989194 being conducted?
This trial has 20 study locations across Alabama, Florida, Louisiana, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02989194's enrollment target sits among peer trials
150 90th of 156 higher than 64 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
RECRUITING · Phase 2
-
Systems Investigation of Vaccine Responses in Aging and Frailty
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI